Inflammation plays an important role in the pathophysiology of many disease processes encountered by anesthesiologists on a daily basis. Major surgery, sepsis, trauma and burns, adult respiratory distress syndrome, and ischemia-reperfusion injuries have inflammatory components. This refresher course addresses the basic mechanisms of inflammation and how inflammatory processes present in the surgical and critical care settings. A review of antiinflammatory therapy and strategies that may decrease inflammatory tissue injury are also discussed. Finally, the concept of postinflammatory immunosuppression is presented.
The Biology of Inflammation

Increased Local Blood Flow
Inflammation is a response to infection or tissue injury that is designed to eradicate the source of injury and facilitate tissue repair. Fundamentally, acute inflammation is a beneficial response that is characterized by increased vascular diameter and flow, exudation of protein-rich fluid, and migration of leukocytes to the site of injury. Initially, inflammation causes an increase in local blood flow. This response is designed to facilitate the transport of leukocytes and soluble mediators to the site of injury or infection. The increase in local blood flow is due to vasodilation caused by nitric oxide (NO) and vasodilating prostaglandins that are produced at the site of injury. Activation of NO synthase in endothelial cells and leukocytes facilitates the production of NO. NO causes vascular smooth muscle relaxation via a transendothelial mechanism mediated by cyclic guanosine monophosphate. Prostaglandins are produced from cell membranederived arachidonic acid through the action of the enzyme cyclooxygenase. Although increased blood flow is an important feature of an effective inflammatory response, systemic activation of vasodilatory pathways may cause hypotension.
Increased Vascular Permeability
The increase in blood flow during inflammation is accompanied by increased vascular permeability. The enhanced vascular permeability results from endothelial cell retraction and the development of transcytoplasmic endothelial cell pores as well as by direct injury caused by trauma or toxic leukocyte products. This response occurs primarily in postcapillary venules and results in the exudation of protein-rich fluid from the vascular compartment into the interstitium. The purpose of the exudative response is to deliver soluble mediators such as antibodies and acute-phase proteins to the site Current Concepts of the Inflammatory Response of injury. The increase in vascular permeability is mediated by several factors, including histamine, bradykinin, platelet-activating factor (PAF), substance P, and leukotrienes. Inappropriate induction of vascular permeability can cause significant fluid flux into tissues and may cause organ dysfunction. The most dramatic example of pathological fluid fluxes is the acute respiratory distress syndrome.
Leukocyte Migration
The migration of leukocytes is another key component of the inflammatory response. The exudation of protein-rich fluid from the vascular compartment results in hemoconcentration and stasis at the site of injury. This process facilitates the movement of leukocytes to the endothelial surface of capillaries and venules, a process called margination. Activation of endothelial cells by proinflammatory cytokines such as tumor necrosis factor α (TNFα) initially induces expression of cell surface proteins called selectins that cause low affinity binding of leukocytes to the endothelial surface. This process keeps leukocytes in close proximity to the endothelium, a process known as rolling. Continued cytokine production further stimulates endothelial cells to express high-affinity adhesion molecules such as intracellular adhesion molecule-1 and vascular cell adhesion molecule-1. Concurrently, leukocytes are induced to express cell surface integrins. The endothelial intracellular adhesion molecules and leukocyte integrins form high-affinity bonds that latch the leukocytes to the endothelial surface. The bound leukocytes subsequently migrate between the endothelial cells and travel to the site of injury. The homing of leukocytes to the site of inflammation is mediated by chemotactic factors such as chemokines, bacterial products, and complement components.
The immune response is tightly controlled and usually functions effectively to limit infection and promote tissue repair. Normally, a balance exists among proinflammatory cytokines such as TNFα, interleukin 1 (IL-1), IL-12, and interferon-γ (IFN-γ) and antiinflammatory signals provided by IL-10, transforming growth factor β, and certain prostaglandins. 1 This balance results in effective activation and subsequent resolution of the inflammatory response. However, in cases where the proinflammatory response predominates, severe systemic inflammation may ensue as typified by sepsis and the systemic inflammatory response syndrome (SIRS; Fig. 1 ). Conversely, predominance of the antiinflammatory response may cause a state of relative immunosuppression to develop. This phenomenon often results after major trauma, thermal injury, or in the postseptic state, and has been termed the counter antiinflammatory response syndrome (CARS). Patients exhibiting CARS may be more susceptible to infectious complications. In either 170 SHERWOOD case, multisystem organ dysfunction, organ failure, and death can occur due to severe inflammation (SIRS) or overwhelming infection (CARS).
Sepsis and the Systemic Inflammatory Response Syndrome
The term SIRS was recommended by the American College of Chest Physicians/ Society for Critical Care Medicine consensus conference in 1992, to describe a systemic inflammatory process independent of its cause. 2 The proposal was based on clinical and experimental results indicating that a variety of conditions, both infectious and noninfectious (i.e., burns, ischemia-reperfusion injury, multiple trauma, pancreatitis, systemic infection), induce a similar host response. Two or more of the following conditions must be fulfilled for the diagnosis of SIRS or sepsis to be made: (1) body temperature greater than 38°C or less than 36°C; (2) heart rate greater than 90 beats/ minute; (3) respiratory rate greater than 20 breaths/minute or arterial carbon dioxide tension less than 32 mm Hg; or (4) leukocyte count greater than 12,000/µl, less than 4,000/µl, or greater than 10% immature (band) forms, all occurring as an acute alteration from baseline in the absence of other known causes for the abnormalities. This definition is very sensitive, and its clinical and prognostic significance has not been conclusively demonstrated. Most of the SIRS criteria are also addressed in other scoring systems of injury-induced physiologic derangement, such as the Acute Physiology and Chronic Health Evaluation, Mortality Probability Model, and Simplified Acute Physiology Severity systems. Several investigators have criticized the definition of SIRS as being too sensitive and nonspecific and encompassing the majority of intensive care unit patients and certainly the vast majority of patients suffering major trauma. 3 The initial definition of SIRS also did not address the continuum of disease severity as was defined for sepsis. Specifically, sepsis was defined by the same criteria as SIRS for patients with demonstrable infection. Severe sepsis included the additional derangements of organ dysfunction, hypotension, and hypoperfusion. Evidence of hypoperfusion included, but was not limited to, lactic acidosis, oliguria, and altered mental status. Septic shock, the most severe form of sepsis, was characterized by hypotension and hypoperfusion requiring the use of inotropes/pressors in patients who were adequately volume resuscitated. In an effort to define a continuum of severity for SIRS, the categories of severe SIRS and sterile shock were later proposed. These conditions were defined by the same criteria as severe sepsis and septic shock in the absence of demonstrable infection.
Several studies have been conducted with the goal of determining the prognostic value of the SIRS designation. 4, 5 In the acute setting, SIRS has been demonstrated in the majority of critically injured patients, and the intensity of the response correlates directly with the severity of injury. The presence of SIRS within the first 24 hours after severe injury has not served as a predictor of mortality in trauma or burn patients in some studies. However, the presence of sterile or septic shock is an important predictor of poor outcome, particularly when associated with multiple system organ dysfunction. In addition, the presence of more than two SIRS criteria in the setting of acute injury correlates with increased morbidity and mortality. Three important factors appear to determine the effect of sepsis or SIRS on the host. The first is the severity of the initial inflammatory response. This response is proportional to the severity of infection or injury. Specifically, the presence of shock or multisystem organ dysfunction within the first 24 hours after injury bears a poor prognosis. The second determinant is the persistence of SIRS beyond the first days of injury. Specifically, prolongation of SIRS beyond the second day after severe trauma or thermal injury is associated with an increased complication rate. The third factor is the adaptive capacity of the host. Extremes of age and the presence of coexisting disease will diminish the adaptive capacity of the host and predict a worse prognosis for any given severity of injury. It is also likely that some individuals are genetically predisposed to develop a more severe inflammatory response to any given injury.
Pathophysiology of Proinflammatory and Antiinflammatory Dysfunction
If injury or infection is severe, the initial host response is designed to maintain perfusion of vital organs such as heart, brain, and kidneys. Activation of the sympathetic nervous system causes an increase in heart rate and peripheral vasoconstriction in an attempt to sustain central perfusion. 6 Perfusion of peripheral tissues such as the gut, skin, and skeletal muscle may be decreased. If the patient is adequately resuscitated, a hyperdynamic state ensues mediated by release of cytokines, noncytokine mediators of inflammation, and epinephrine. Peripheral vasodilation and high cardiac output characterize this response. However, dysregulation of this response can result in inflammatory injury. The inflammatory response may be severe if the initial injury was extensive or if prolonged ischemia of peripheral organs occurred due to inadequate resuscitation. Tissue hypoperfusion is a common event following major trauma or burns. Reperfusion of ischemic tissues can result in further cellular injury. Ischemia-reperfusion injury is mediated, in large part, by reactive oxygen species such as hydrogen peroxide, superoxide anion, and hydroxyl free radicals. These free radicals not only cause direct cellular injury by peroxidation of membrane lipids but also activate the inflammatory cascade. 7 Systemic inflammation is associated with increased circulating cytokine levels, activation of the clotting cascade, and release of vasoactive mediators such as NO. High systemic cytokine levels may result in myocardial dysfunction, altered intracellular oxygen utilization and direct inflammatory injury. Activation of the clotting cascade can cause microvascular thrombosis and tissue hypoperfusion. Increased production of NO and metabolites such as peroxynitrite can lead to peripheral vasodilation, decreased peripheral vascular resistance, and hypotension. Taken together, these factors result in sequelae that are characteristic of sepsis and SIRS such as hypotension, tissue hypoperfusion, metabolic dysfunction, and impaired oxygen utilization ( Fig. 2) .
Antiinflammatory mechanisms are also activated following tissue injury or infection to regulate the inflammatory response. 8 After sepsis or severe trauma, overactivation of antiinflammatory mechanisms can result in a state of immunosuppression. Specifically, the production of proinflammatory cytokines such as TNFα, IL-1, IL-12, IL-15, and IFN-γ are suppressed. Expression of the class II major histocompatability complex (MHC-II), which is essential for effective antigen presentation and activation of acquired immunity, is decreased. The responsiveness of T-cells to proinflammatory cytokines and to antigen presentation is impaired. These alterations result in decreased resistance to infection.
Cytokine and Noncytokine Mediators of Sepsis and Systemic Inflammatory Response Syndrome
Cytokines
Cytokines comprise a broad group of polypeptides with varied functions within the immune response (Table 1 ). 9 The classical mediator of systemic inflammation is TNFα. TNFα is released primarily by macrophages within minutes of local or systemic injury 172 SHERWOOD and modulates a variety of immunologic and metabolic events. At sites of local infection or inflammation, TNFα initiates an immune response that activates antimicrobial defense mechanisms and, once the infection is eradicated, tissue repair. It is a potent activator of neutrophils and mononuclear phagocytes and also serves as a growth factor for fibroblasts and as an angiogenesis factor. However, systemic release of TNFα can precipitate a destructive cascade of events that can result in tissue injury, organ dysfunction, and potentially death. Among the systemic effects of TNFα are the induction of fever, stimulation of acute-phase protein secretion by the liver, activation of the coagulation cascade, myocardial suppression, induction of systemic vasodilators with resultant hypotension, catabolism, and hypoglycemia. Several studies have shown that administration of TNFα to experimental animals will mimic the systemic inflammatory response observed in sepsis and after severe injury. Another important effect of TNFα is its ability to induce apoptosis of a variety cell types. The physiological effects of IL-1 are essentially identical to those of TNFα. However, IL-1 does not induce tissue injury or apoptotic cell death by itself but can potentiate the injurious effects of TNFα. The IL family of proteins, including IL-18, are the only group of cytokines for which known natural antagonists have been identified. The IL-1 receptor antagonists bind to the IL-1 receptor but do not induce receptor activation. These proteins appear to function as competitive inhibitors of IL-1 action.
Interleukin-6 is commonly increased in the circulation of patients with SIRS. 10 Macrophages, endothelial cells, and fibroblasts secrete this protein. The primary effect of IL-6 is to induce secretion of acute-phase proteins from the liver as well as serve as a growth and differentiation factor for B-lymphocytes. Although IL-6 does not appear to directly mediate tissue injury, persistent elevation of plasma IL-6 levels has been reported to correlate with poor outcome. In this regard, IL-6 may serve as a marker of ongoing inflammation.
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Interferon-γ is a cytokine involved in the amplification of the acute inflammatory response, particularly the stimulation of cytokine secretion, phagocytosis, and respiratory burst activity by macrophages. 11 IFN-γ is secreted primarily by T-lymphocytes and natural killer cells in response to antigen presentation as well as macrophagederived cytokines such as IL-12 and IL-18. The primary effect of IFN-γ is to amplify the inflammatory response of macrophages. Blockade of IFN-γ production or function has 174 SHERWOOD been shown to markedly decrease the deleterious inflammatory effects induced by bacterial endotoxin. Therefore, IFN-γ is believed to be an important factor in the amplification of sepsis and SIRS.
Chemokines
Chemokines are a family of proteins that function primarily as chemotactic factors for leukocytes. IL-8 is the most widely studied chemokine in the setting of sepsis and SIRS. IL-8 is a potent chemoattractant for neutrophils and is a major factor in recruiting neutrophils to inflammatory foci. Several studies have shown that IL-8 plays a role, particularly in the lung, in mediating tissue injury in the setting of trauma and burn injury. 12 It is likely that that other chemokines also play a role in inflammatory injury.
Nuclear Factor κB
A central feature in the regulation of inflammatory gene product expression is the transcription factor nuclear factor κB (NF-κB). 13 NF-κB is composed of a family of proteins that regulate the transcription of a variety of cytokine, chemokine, adhesion molecule, and enzyme genes involved in SIRS. NF-κB is constitutively expressed in many cell types and sequestered in the cytoplasm of cells in a functionally inactive form. Bacterial endotoxin, TNFα, IL-1, and reactive oxygen species activate signal transduction cascades, resulting in the nuclear translocation of NF-κB and activation of genes encoding proinflammatory factors (Fig. 3 inflammation and sepsis, induces NF-κB translocation after binding to the endotoxin receptor complex composed of CD14, toll-like receptor 4 (TLR-4), and a linking protein known as MD-2. TLR-4 is a member of the TLR family of proteins that play critical roles in cell signaling in response to bacteria and bacterial products. 14 Activation of the endotoxin receptor complex results in activation of inhibitory κB kinase, causing phosphorylation and degradation of inhibitory κB with subsequent release and translocation of NFκB into the nucleus. Increased activation of NF-κB during sepsis or SIRS has been associated with poor outcome in some studies.
Noncytokine Mediators of Sepsis
Several noncytokine factors have been implicated in the pathogenesis of SIRS. 15 PAF is a phospholipid autocoid released by endothelial cells that regulates the release of cytokines and amplifies the proinflammatory response. It appears to be an important factor in the adhesion of neutrophils to endothelial cells. The prolonged presence of PAF in the serum of patients with SIRS has correlated with poor outcome. Eicosanoids are arachidonic acid metabolites that regulate many aspects of the immune response. Leukotrienes (LTC 4 -LTE 4 ) induce contraction of endothelial cells and encourage capillary leakage. Thromboxane A 2 , a macrophage and platelet-derived factor, promotes platelet aggregation, vasoconstriction, and, potentially, tissue thrombosis.
The Coagulation Cascade
Proinflammatory cytokines and infectious agents stimulate tissue factor expression by macrophages and endothelial cells. 16 Tissue factor promotes thrombin formation and clotting primarily by activation of the extrinsic clotting pathway. In addition, inflammatory mediators stimulate production of plasminogen activator inhibitor 1, which suppresses fibrinolysis and promotes clot retention. Evidence also indicates that thrombin amplifies inflammatory mechanisms, resulting in a vicious cycle of coagulation and inflammation. These interactions potentiate both the inflammatory cascade and tissue thrombosis in cases of sepsis and severe trauma. Mechanisms normally function to inhibit overactivation of the clotting cascade. One mechanism is production of activated protein C. 17 Protein C is activated by the thrombin-thrombomodulin complex. Thrombomodulin is expressed on the surface endothelial cells and binds thrombin. The thrombin-thrombomodulin complex activates protein C, which inhibits coagulation by proteolysis of activated factors V and VIII. Activated protein C also inhibits the production of proinflammatory cytokines by activated leukocytes. Therefore, activated protein C inhibits both procoagulant and proinflammatory pathways.
Complement
The complement cascade is composed of more than 30 proteins that interact in a complex fashion to mediate inflammation and direct lysis of microbes and other cells. 18 However, in SIRS, excessive complement activation appears to cause significant cellular injury in the host. Products of the complement cascade, most notably C3a and C5a, are potent activators of inflammation and leukocyte chemotaxis. C3a and C5a also directly activate neutrophils and promote release of reactive oxygen intermediates and proteases. Excessive release of these factors can result in significant tissue injury. The membrane attack complex is the terminal component of the complement cascade and results from the aggregation of the complement components C5-C9 on biological membranes. The accumulation of membrane attack complex on cell surfaces can result in significant tissue and cellular injury and may be a major factor in the pathogenesis of multiple-system organ dysfunction.
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Antiinflammatory Therapy
Inhibition of Endotoxin and Endotoxin-signaling Mechanisms
Despite our increased understanding of the role of inflammatory mediators in the pathogenesis of sepsis and SIRS, most antiinflammatory drug regimens have had little success in the treatment of sepsis. A variety of strategies have been used. At the most basic level, blockade of endotoxin and the endotoxin receptor, CD14, have not been beneficial in the treatment of experimental sepsis (Fig. 3) . Recent research has demonstrated the key role of the TLRs, particularly TLR-4, for transduction of intracellular signals following activation of target cells by endotoxin. As discussed previously, TLR-4-transduced signals primarily result in nuclear translocation of the transcription factor NF-κB, causing induction of proinflammatory gene transcription. Specific targeting of TLR-4 and NF-κB for the treatment of sepsis is a major area of research but has not yet translated into effective experimental or clinical treatment approaches for sepsis.
Blockade of Inflammatory Mediators
A widely studied approach for the treatment of sepsis is the blockade of proinflammatory mediators (Fig. 4 ). Blockade of numerous inflammatory mediators, including TNFα, IL-1, PAF, bradykinin, and prostaglandins, has been extensively studied in clinical sepsis. 19 One of the most widely studied approaches for the treatment of sepsis and SIRS is blockade of TNFα using soluble TNF receptors or monoclonal antibodies to TNFα. Several multicenter, prospective clinical trials have been undertaken in septic patients using anti-TNFα strategies. These studies did not demonstrate improved outcome for patients receiving anti-TNFα compared with placebo. Similarly, the use of soluble TNF receptors as a strategy to neutralize the systemic effects of TNFα and decrease sepsis-associated morbidity and mortality has been unsuccessful. Other antiinflammatory approaches that have been studied and found to be largely ineffective include the use of IL-1 receptor antagonists, antibradykinin, PAF receptor antagonists, and ibuprofen.
Because of the relative ineffectiveness of therapy aimed at neutralizing single mediators, more broad-based strategies were developed with the goal of neutralizing, removing, or inhibiting the production of several inflammatory mediators. Hemofiltration is one approach that has received considerable attention. 20 Several studies have shown that hemofiltration will increase the clearance of inflammatory mediators, particularly IL-6, from the blood of patients with sepsis. However, none of these studies has demonstrated a significant reduction in IL-6 plasma levels. Overall, the use of hemofiltration has been largely ineffective in removing significant amounts of inflammatory mediators from the blood of patients with sepsis, and there is currently no evidence that this approach will decrease morbidity and mortality.
Corticosteroids
The use of glucocorticoids in the treatment of sepsis has been proposed for more than 30 years. Two metaanalyses of studies using high-dose glucocorticoids in the treatment of sepsis were published in 1995, and later summarized by Zeni et al. 21 Overall, the use of short-term, high-dose glucocorticoids to treat sepsis and septic shock has not been beneficial. In many studies, the use of glucocorticoids in septic patients was associated with increased mortality. In burn patients, there is no evidence that high-dose administration of glucocorticoids provides effective treatment for systemic inflammation. However, recent studies have shown that lower-dose corticosteroids given over a 7-to 10-day period and tapered may improve survival in catecholaminerefractory septic shock. 22 Evidence indicates that this approach may be beneficial because of its ability to increase vascular responsiveness to catecholamines and reverse adrenal insufficiency associated with advanced sepsis.
Complement Antagonism
Strategies aimed at decreasing the injurious effects of the complement system have also been investigated. 18 Several experimental studies using anticomplement strategies have shown decreased organ dysfunction and improved outcome. This approach has been used in experimental models of sepsis, ischemia-reperfusion injury, and adult respiratory distress syndrome. Clinical studies have been initiated based on these results. Anticomplement strategies include the use of soluble complement inhibitors,
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FIG. 4. Results of clinical trials for antiinflammatory agents in sepsis. A synopsis indicative of the overall results of several clinical trials using antiinflammatory approaches to the treatment of sepsis. Overall, significant improvements in survival were not demonstrated in these trials. TNF-mAb = tumor necrosis factor α monoclonal antibody; sTNFR = soluble tumor necrosis factor receptor; IL-1ra = interleukin-1 receptor antagonist; PAFra = platelet-activating factor receptor antagonist. Adapted with permission from Natanson et al. 19 neutralizing antibodies to complement components, and up-regulation of endogenous complement inhibitors. Whether these strategies will prove to be effective will be determined by the ongoing clinical trials.
Blockade of Procoagulant Mechanisms
Activation of the coagulation cascade by tissue factor not only facilitates tissue thrombosis but also amplifies the proinflammatory response. 17 The coagulation cascade is regulated, in part, by activated protein C. Protein C limits the production of thrombin by inactivating factors Va and VIIIa. The decrease in thrombin formation not only inhibits fibrin clot formation, but also decreases inflammation. Recent studies have shown that administration of activated protein C in severe sepsis will improve 28-day survival by approximately 20%. 17 This improvement in survival was associated with evidence of attenuated inflammation as well as decreased fibrin deposition. Further studies are underway to better characterize the benefits of activated protein C in the treatment of sepsis. Recent studies also show that antithrombin III treatment may improve outcome in clinical sepsis. 23 Administration of antithrombin III in combination with heparin did not improve 28-day survival in patients with severe sepsis and was associated with an increased incidence of hemorrhage compared with placebo. When antithrombin III was administered alone in severe sepsis, a trend toward increased survival was noted at 28 days, which was significant at the 90-day time point. Overall, the use of anticoagulant strategies, particularly activated protein C and antithrombin III, has shown promise for the treatment of sepsis. Additional studies are required to fully determine the benefit of this approach.
Antioxidants
The use of antioxidants and other mechanisms to protect cells from injury during severe inflammation has also been studied. The use of antioxidant vitamins such as vitamins C and E has not been well studied in clinical sepsis. N-acetylcysteine, an oxygen scavenger, has been shown to improve oxygenation and decrease length of mechanical ventilation if given early in sepsis. 24 However, mortality or the incidence of organ failure were not significantly improved in patients treated with N-acetylcysteine. One study showed that starting N-acetylcysteine more than 24 hours after the onset of acute lung injury was associated with a worse prognosis. 25 Selenium is an element that is required for a variety of metabolic functions and also possesses antioxidant properties. Selenium becomes depleted in severely septic patients, and low selenium levels have correlated with increased mortality in sepsis. However, selenium replacement has not been shown to improve survival in septic patients. 26 
General Approaches to Minimize Inflammatory Injury
Factors that appear to be important in limiting the extent of inflammatory and oxidative injury, and in many cases decreasing the incidence of shock and organ dysfunction, are adequate fluid resuscitation, optimization of tissue perfusion and oxygen delivery, excision of necrotic tissue, and adequate nutritional support. 15, 16 Several parameters have been used to assess the adequacy of volume resuscitation in critically injured patients. Regardless of the parameter used, a critical factor is early volume resuscitation and establishment of tissue perfusion. There is controversy regarding the ideal fluid for volume resuscitation in trauma and burn patients. However, recent studies show that hypertonic saline has beneficial effects in modulating the SIRS-associated immunological cascade as well as restoring hemodynamic parameters and microcirculatory flow. Recent studies have shown that resuscitation with hypertonic saline will improve macrophage and T-cell function as well as increase resistance to infection in experimental models or trauma and hemorrhage. Proper nutritional support is also an important factor in the treatment of severely injured patients. Enteral feeding formulas supplemented with glutamine, arginine, omega-3 fatty acids, and nucleotides have been shown to improve outcome in trauma patients. Overall, trauma patients receiving immune-enhancing diets have been shown to have fewer infectious complications.
Postinflammatory Immunosuppression
Numerous studies have shown suppression of antimicrobial immunity in patients suffering severe trauma or sepsis. Innate immunity plays a key role in the initial response to infection. Macrophages and dendritic cells recognize microbial products such as exotoxins, endotoxins, and bacterial cell wall components and initiate responses that ultimately mobilize nonspecific (innate) and organism-specific (adaptive) immunity. Macrophage and dendritic cell activation causes the production of a variety of cytokines, chemokines, and noncytokine regulatory factors. These factors activate inflammatory responses that ultimately result in fluid transmigration and leukocyte recruitment to the site of infection and usually coordinate effective clearance of the invading pathogen. Macrophages and dendritic cells also secrete IL-12, which activates natural killer cells and stimulates secretion of IFN-γ. IFN-γ amplifies macrophage and dendritic cell functions such as phagocytosis, respiratory burst activity, and antigen presentation. In addition, IFN-γ potentiates the induction of cytokine and chemokine secretion by macrophages and dendritic cells. This response amplifies the expression of adhesion molecules by endothelial cells and leukocytes, causing increased adherence and transmigration of neutrophils to the site of acute infection. Results from our laboratory and others also show that costimulatory signals provided by IL-15, IL-18, and B7 proteins are important for IL-12-induced secretion of IFN-γ by natural killer cells. 27 IL-10 serves as a potent inhibitor of IL-12 and IFN-γ secretion. The balance between amplifying signals provided by IL-12 and IFN-γ with inhibitory input from factors such as IL-10 results in an effective innate response to infection.
Activation of adaptive immunity is also critical for an effective antimicrobial response. Antigen presentation, in conjunction with secretion of IL-12 and its costimulatory factors, causes activation of a microbe-specific cell-mediated and humoral response. Microbial antigens are presented to T-cells in conjunction with the MHC-II expressed on the surface of antigen presenting cells such as macrophages and dendritic cells. The antigen-MHC-II complex activates the T-cell receptor complex on T-lymphocytes, causing secretion of IL-2 and T-cell proliferation. Activated type 1 T-lymphocytes also secrete IFN-γ, which further amplifies macrophage and dendritic cell function, stimulates secretion of opsonizing antibodies by B-lymphocytes, and activates cytotoxic T-cells. The type 1 T-cell response is the primary response elicited by bacterial pathogens. Therefore, IFN-γ plays a key role in the amplification of both innate and acquired antimicrobial immunity. The functional significance of IFN-γ in antimicrobial defense is demonstrated by increased susceptibility of IFN-γ-and IFN-γ receptor-deficient mice to a variety of infections, particularly to intracellular organisms such as Listeria, Salmonella, and Mycobacteria species.
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Therapeutic Approaches for the Treatment of Injury-induced Immunosuppression
A widely accepted treatment for injury-induced immunosuppression has not yet been developed. This can be attributed, in part, to the fact that relatively few clinical studies have been undertaken to address this problem, as well as our likely lack of understanding of the intricacies of injury-induced immunosuppression. In addition, it is possible that many approaches to the treatment of postinflammatory immunosuppression might worsen ongoing inflammatory injury. A key factor in the implementation of immunopotentiating treatments is characterization of the host inflammatory state. Several markers have been identified that may correlate with the presence of ongoing inflammation or immunosuppression in critically ill patients (Fig. 5 ). Markers of inflammation include TNFα, IL-1, IL-6, and IL-8. The presence of increased serum levels of IL-10, soluble TNF receptors, or IL-1 receptor antagonist may indicate an antiinflammatory state. The reliability of these markers remains to be fully established. Better understanding of the temporal changes in immune function following severe injury is essential.
One of the most extensively studied agents for the treatment of injury-induced immunosuppression is IFN-γ. Administration of IFN-γ in experimental models of trauma has been shown to enhance immune function and increase resistance to infectious challenge. 28 Clinical studies have shown that administration of IFN-γ to immunosuppressed septic patients enhances HLA-DR expression and proinflammatory cytokine production. 28 Prophylactic administration of IFN-γ to critically injured patients has also been demonstrated to decrease the incidence and severity of infections. However, a recently published phase III clinical trial did not demonstrate a reduction in infection or mortality in thermally injured patients receiving IFN-γ. 29 Assessment of patient subsets in many of these clinical studies have shown that IFN-γ therapy was most beneficial to severely injured patients who were at the highest risk of developing infectious complications. Therefore, the development of diagnostic tests, such as determination of HLA-DR expression, that can identify high-risk patients with suppressed immune function may allow for a more targeted administration of IFN-γ and other immunomodulators. Although initial clinical trials with IFN-γ have not shown broad benefit in trauma patients, a better understanding of when and to whom this drug should be administered may allow realization of improved immune function and outcome in high-risk patients.
Interleukin-12 therapy has shown promise in enhancing resistance to infection in experimental models of trauma-induced immunosuppression. IL-12 has been shown to enhance resistance to polymicrobial sepsis and herpes simplex virus type 1 (HSV-1) infection in models of thermal injury 30, 31 but has not been used in a clinical setting to date. Administration of IL-12 in experimental models of trauma has correlated with increased type 1 T-cell expression with associated enhancement of IFN-γ production. Furthermore, the beneficial effect of IL-12 therapy was abrogated by the coadministration of antibodies to IFN-γ. In further studies, Kobayashi et al. 32 showed that coadministration of IL-12 with soluble IL-4 receptor (sIL-4R) will enhance resistance to HSV-1 in thermally injured mice. In these studies, administration of either IL-12 or sIL-4R alone in a therapeutic regimen did not protect thermally injured mice from HSV-1 infection. However, administration of IL-12 and sIL-4R in combination improved survival and enhanced cell-mediated immunity in a postburn model of HSV-1 infection. Taken together, these studies demonstrate the potential benefit of IL-12, administered either alone or in combination with other immunopotentiating agents, in the treatment of injury-associated immunosuppression.
Several experimental therapeutic approaches have focused on inhibiting the activity of immunosuppressive cytokines. Antibodies to the immunosuppressive cytokine IL-10 have been shown to restore immune function and resistance to infection in thermally injured mice. 33 However, a recently published study, 34 which used IL-10 knockout mice, did not demonstrate an essential role of IL-10 in the development of T-cell dysfunction following thermal injury. Studies have also been undertaken to determine the effect of IL-4 inhibitors in an experimental model of postinjury infection. As outlined above, administration of sIL-4R alone did not protect mice in an experimental model of postburn HSV-1 infection but potentiated the protective effect of IL-12. As stated previously, another immunosuppressive factor that appears to play a role in injury-induced immunosuppression is prostaglandin E2. The key enzyme mediating production of prostaglandin E2 is cyclooxygenase-2. Studies by Shoup et al. 35 using a model of Pseudomonas burn wound infection showed increased survival, decreased prostaglandin E2 levels, and improved neutrophil counts in mice receiving a cyclooxygenase-2 inhibitor. None of the antiinhibitory approaches have been studied in the clinical setting, but these early experimental studies suggest that this approach may be beneficial when administered either alone or in combination with immunopotentiating agents.
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Intravenous immunoglobulins are administered to critically ill patients in several countries around the world. A recent metaanalysis 36 showed improved mortality in critically ill patients treated with immunoglobulins. Intravenous immunoglobulins have also been shown to improve survival in septic neonates. 37 Many of these studies enrolled small numbers of patients. This promising approach may prove beneficial in future, large-scale clinical trials.
Conclusions
Anesthesiologists care for a variety of patients in whom inflammatory processes play an important role in disease pathogenesis. Our understanding of the cellular and molecular mechanisms causing inflammatory injury has advanced markedly during the last decade. However, this knowledge has not yet translated into major advances in the treatment of systemic inflammatory syndromes. Currently, meticulous attention to details such as adequate volume resuscitation, optimization of tissue perfusion and oxygen delivery, aggressive treatment of infection, removal of necrotic tissue, and enteral feeding provide mechanisms for improving recovery in patients suffering critical injury and sepsis. Ongoing research is likely to identify effective treatment for sepsis and postinflammatory immunosuppression.
